From the Departments of Neurology (C.B., M.v.H., R.H., B.R.B., M.U.F.), Rehabilitation (J.N., V.W.), and Otorhinolaryngology (A.J.), Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, and Department of Biophysics (R.v.W.), Radboud University, Nijmegen, the Netherlands; Department of Clinical Neurophysiology (A.D.), Lille University Medical Center, France; Sint Maartenskliniek Research, Development & Education (V.W.), Nijmegen, the Netherlands; Grenoble Alpes University (B.D.); Grenoble Institute of Neurosciences (B.D.), INSERM U1216, France; and Biomedical Signal and Systems Group (J.N., R.v.W., M.U.F.), MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands.
Neurology. 2018 Jan 9;90(2):e164-e171. doi: 10.1212/WNL.0000000000004795. Epub 2017 Dec 20.
To assess, in a cross-sectional study, the feasibility and immediate efficacy of laser shoes, a new ambulatory visual cueing device with practical applicability for use in daily life, on freezing of gait (FOG) and gait measures in Parkinson disease (PD).
We tested 21 patients with PD and FOG, both "off" and "on" medication. In a controlled gait laboratory, we measured the number of FOG episodes and the percent time frozen occurring during a standardized walking protocol that included FOG provoking circumstances. Participants performed 10 trials with and 10 trials without cueing. FOG was assessed using offline video analysis by an independent rater. Gait measures were recorded in between FOG episodes with the use of accelerometry.
Cueing using laser shoes was associated with a significant reduction in the number of FOG episodes, both "off" (45.9%) and "on" (37.7%) medication. Moreover, laser shoes significantly reduced the percent time frozen by 56.5% (95% confidence interval [CI] 32.5-85.8; = 0.004) when "off" medication. The reduction while "on" medication was slightly smaller (51.4%, 95% CI -41.8 to 91.5; = 0.075). These effects were paralleled by patients' positive subjective experience on laser shoes' efficacy. There were no clinically meaningful changes in the gait measures.
These findings demonstrate the immediate efficacy of laser shoes in a controlled gait laboratory, and offer a promising intervention with potential to deliver in-home cueing for patients with FOG.
This study provides Class III evidence that for patients with PD, laser shoes significantly reduce FOG severity (both number and duration of FOG episodes).
在一项横断面研究中评估激光鞋(一种新的、具有实际应用价值的可穿戴视觉提示装置)对冻结步态(FOG)和帕金森病(PD)步态测量的可行性和即时疗效。
我们测试了 21 名 PD 伴 FOG 患者,其药物状态为“开”或“关”。在受控步态实验室中,我们测量了在包括 FOG 诱发情况的标准化行走方案中发生的 FOG 发作次数和冻结时间百分比。参与者进行了 10 次有提示和 10 次无提示的试验。FOG 通过独立评分者的离线视频分析进行评估。步态测量使用加速度计在 FOG 发作之间记录。
使用激光鞋提示与 FOG 发作次数的显著减少相关,药物“开”和“关”状态下分别减少 45.9%和 37.7%。此外,当药物“关”时,激光鞋可使冻结时间百分比显著减少 56.5%(95%置信区间 [CI] 32.5-85.8; = 0.004)。药物“开”时的减少幅度略小(51.4%,95% CI -41.8 至 91.5; = 0.075)。这些效果与患者对激光鞋疗效的积极主观体验相平行。步态测量没有出现临床意义上的变化。
这些发现表明激光鞋在受控步态实验室中具有即时疗效,并提供了一种有前景的干预措施,有可能为 FOG 患者提供家庭提示。
本研究提供了 III 级证据,表明对于 PD 患者,激光鞋可显著减轻 FOG 严重程度(FOG 发作次数和持续时间)。